Health Care

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Sees Price Increase - Up by 67.85%

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Sees Price Increase - Up by 67.85%”

The 50 day moving average was up $4.11 or +65.33% and the 200 day average was up $4.11.

A number of large investors have recently modified their holdings of the company. The value of the investment in (ZYNE) went from $1,516,000 to $1,534,000 a change of $18,000 quarter to quarter.

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. Vanguard Group Inc. now owns 425,811 shares of the company's stock valued at $8,559,000 after purchasing an additional 149,094 shares in the last quarter.

Hain Celestial stock is up 5% at $42.40 thanks to news the company has come to an agreement with activist investor Engaged Capital to overhaul its board, opening the door for a sale of the company down the road. ZYNE shares are up over 70% from yesterday's close of $6.19 and have reached as high as $11.28 in early trading. Zynerba Pharmaceuticals has a one year low of $6.02 and a one year high of $23.75. The company's market cap is $77.42 million. The firm has a 50 day moving average price of $20.69 and a 200 day moving average price of $16.55.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) stock has greatly underperformed both the indexes and industry this year. The company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.04.

As of the latest earnings report the EPS was $-2.60 and is expected to be $-2.42 for the current year with 13,257,000 shares now outstanding.

Several equities research analysts have issued reports on ZYNE shares.

Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs.

On the ratings front, ZYNE stock has been the subject of a number of recent research reports.

August 21 investment analysts at Canaccord Genuity made no change to the stock rating of "Buy" and lowered the price expectation to $9.00 from $35.00. H.C. Wainwright initiated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) on Friday, October 7 with "Buy" rating. Oppenheimer initiated it with "Outperform" rating and $40.0 target in Tuesday, September 8 report. If you are reading this news story on another domain, it was illegally copied and reposted in violation of United States & worldwide trademark and copyright law.

Analysts await Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to report earnings on November, 13. The reason? The cannabis biotech company announced positive top line results from an open label exploratory Phase 2 FAB-C (Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS).



Like this

loading...
loading...

Latest


29 September 2017
Kurdish bid for independence from Iraq emerges as regional flash point
Lebanon's Middle East Airlines, EgyptAir and Royal Jordanian announced Wednesday that flights would be suspended beginning Friday evening.

29 September 2017
First Horizon National Corporation (FHN): What are the Technicals Saying?
On Tuesday, Shares of First Horizon National Corporation (NYSE: FHN ) expressed a change of 0.85% and is now trading at $18.30. If you are reading this story on another site, it was illegally copied and reposted in violation of US & global copyright law.

29 September 2017
Home Bancshares, Inc. (Conway, AR) (HOMB)
In the most updated research from a number of analysts on Wall Street, the company gets 4 Buys and 0 Sell among 8 analysts. Allison acquired 15,000 shares of Home BancShares stock in a transaction that occurred on Monday, July 24th.

29 September 2017
Puri's next Mehbooba with son Akash
What is interesting with Mehbooba is that the director promises it to be a first of its kind of film in his repertoire. Puri's Next Titled Mehbooba :- Sensational filmmaker Puri Jagannadh is sure one of the finest filmmakers of Tollywood.

29 September 2017
WWE Hit The Young Bucks With A Cease & Desist Order
Right now, WWE's wish is that The Bucks stop using "Too Sweet " in-ring and on merchandise. "They are trying to do just that". Pro Wrestling Sheet stated that WWE wants an agreement promising that they'll not infringe on WWE's intellectual property.

29 September 2017
Vettel says he still has opportunity to close gap with Hamilton
Hamilton extended his lead in the championship to 28 points with victory in Singapore after Vettel crashed out on the opening lap. I went into it thinking I would lose a lot of points to Sebastian, so to come out the other way around it was a real surprise.

29 September 2017
Eaton Vance Ltd Duration Income Fund (EVV) Share Activity Climbing in Session
The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. Taking a peek at some Moving Averages, the 200-day is at 12.44, the 50-day is 12.58, and the 7-day is sitting at 12.64.

29 September 2017
'It starts with us': Broncos say 'we'll be standing together'
This is after Pittsburgh Steelers coach Mike Tomlin said, "I'm an advocate for those that simply want to do their jobs". The Broncos will stand together for the national anthem on Sunday, the team announced on Thursday.

29 September 2017
Putin arrives in Ankara for talks with Erdogan
On Iraq, Turkey has strongly opposed an Iraqi Kurdish referendum on independence which Russian Federation neither supported nor condemned.

29 September 2017
EPS for Canadian Pacific Railway Limited (USA) (CP) Expected At $2.38
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Eaton Vance Management grew its holdings in shares of Canadian National Railway by 5,323.4% during the second quarter.